

Technology Advisory Committee A Interests Register


Olaparib in combination with bevacizumab for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy with bevacizumab [Review of TA693] [ID4066]

Publication Date: 11/10/2023

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
Becky Pennington	TAC A Committee Member	Direct - Financial Interests	Becky received consultancy fees from Roche and Takeda for research/advice into including carer health-related quality of life in economic evaluation. Neither project was drug or disease-area specific and did not relate to either bevacizumab or alogliptin.	19/05/2023	N/A	It was agreed that Becky's declaration would not prevent her from participating in discussions on this appraisal.
Becky Pennington	TAC A Committee Member	Direct - Financial Interests	Becky received consultancy fees from Takeda & Roche for methods research on carers' HRQL (not specific to any drug / indication and not related to the topics here).	10/07/2023	N/A	It was agreed that Becky's declaration would not prevent her from participating in discussions on this appraisal.



Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
Dr Steve Edwards	TAC A Committee Member/EAG		Steve was a member of the EAG for olaparib (ID4066) and so could not attend as a committee member for the topic.	17/05/2023	N/A	It was agreed that Steve's declaration would prevent him from participating in discussions on this appraisal as a committee member.
Steven Lloyd	TAC C Vice Chair	Non-Financial Professional & Personal Interests	Comparator company is Pfizer – Steve has undertaken paid educational work for covid treatments for HCPs sponsored by this company in the past.	01/06/2023	N/A	It was agreed that Steven's declaration would not prevent him from participating in discussions on this appraisal.
Anna Hudson	Head of Support Services at Ovacome Ovarian Cancer Charity	Indirect - financial	Ovacome Ovarian Cancer Charity has received funding from various drug companies, but no conflicts of interest.	01/06/2023	N/A	It was agreed that Anna's declaration would not prevent her from participating in discussions on this appraisal.
Professor Iain McNeish	Professor of Oncology at Imperial	Direct – financial	lain has sat on Advisory Boards for AstraZeneca – these have all related to the	06/10/2022	N/A	It was agreed that lain's declaration would not prevent him from



Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
	College London		use of PARP inhibitor therapy in ovarian cancer.			participating in discussions on this appraisal.
Professor Iain McNeish	Professor of Oncology at Imperial College London	Indirect – financial	lain's My institution, Imperial College London, has received grant income from AstraZeneca.	06/10/2022	N/A	It was agreed that lain's declaration would not prevent him from participating in discussions on this appraisal.